Alpha 2.0
Login Register
» Authors » Francesco Vaia

Francesco Vaia

Explore the profile of Francesco Vaia including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 84
Citations 1239
Followers 0
Related Specialties
Infectious Diseases
Microbiology
General Medicine
Top 10 Co-Authors
Andrea Antinori
Enrico Girardi
Emanuele Nicastri
Fabrizio Maggi
Valentina Mazzotta
Giulia Matusali
Francesca Colavita
Roberta Gagliardini
Carmela Pinnetti
Annalisa Mondi
Published In
Int J Infect Dis
Vaccines (Basel)
Lancet Infect Dis
J Clin Med
J Med Virol
Affiliations
Soon will be listed here.
Recent Articles
1.
Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
Mazzotta V, Piselli P, Lepri A, Matusali G, Cimini E, Esvan R, et al.
Vaccines (Basel) . 2025 Jan; 13(1). PMID: 39852811
Background: The recent resurgence of mpox in central Africa has been declared a new public health emergency of international concern (PHEIC) requiring coordinated international responses. Vaccination is a priority to...
2.
The Italian National Vaccine Prevention Plans, 1999/2020-2023/2025: challenges and obstacles to vaccine coverage goals. Commentary
Signorelli C, Oleari F, Greco D, Ruocco G, Guerra R, Rezza G, et al.
Ann Ist Super Sanita . 2024 Dec; 60(4):247-251. PMID: 39699977
Five consecutive national vaccination plans (from 1999 to 2025) were revised, outlining their objectives, challenges, and results. Vaccination coverage for children consistently approached target levels, though regional differences emerged. In...
3.
Predictors of Mortality and Orotracheal Intubation in Patients with Pulmonary Barotrauma Due to COVID-19: An Italian Multicenter Observational Study during Two Years of the Pandemic
Tetaj N, De Pascale G, Antonelli M, Vargas J, Savino M, Pugliese F, et al.
J Clin Med . 2024 Mar; 13(6). PMID: 38541932
Coronavirus disease 2019 (COVID-19) is a significant and novel cause of acute respiratory distress syndrome (ARDS). During the COVID-19 pandemic, there has been an increase in the incidence of cases...
4.
Public health genomics research in Italy: an overview of ongoing projects
Pitini E, Baccolini V, Isonne C, Maran P, Marzuillo C, Villari P, et al.
Front Public Health . 2024 Mar; 12:1343509. PMID: 38450143
Public health genomics (PHG) aims to integrate advances in genomic sciences into healthcare for the benefit of the general population. As in many countries, there are various research initiatives in...
5.
Nutrition, Physical Activity and Smoking Habit in the Italian General Adult Population: CUORE Project Health Examination Survey 2018-2019
Donfrancesco C, Buttari B, Marcozzi B, Sieri S, Di Lonardo A, Lo Noce C, et al.
Healthcare (Basel) . 2024 Feb; 12(4). PMID: 38391850
Background: Tobacco consumption, incorrect nutrition and insufficient physical activity/sedentariness represent modifiable NCDs risk factors in Western countries. To evaluate recent lifestyle indicators in Italy, data from the national Health Examination...
6.
The role of pharmacies in the implementation of vaccination cover- age in Italy. Insights from the preliminary data of the Lombardy Region
Pennisi F, Mastrangelo M, De Ponti E, Cuciniello R, Mandelli A, Vaia F, et al.
Ann Ig . 2024 Feb; 36(3):363-369. PMID: 38386026
Introduction: The administration of vaccines in pharmacies was not allowed in Italy until 2021. During the COVID-19 pandemic, legislative innovations were introduced that now allow qualified pharmacists to administer anti-flu...
7.
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
Mazzotta V, Lepri A, Matusali G, Cimini E, Piselli P, Aguglia C, et al.
EClinicalMedicine . 2024 Jan; 68:102420. PMID: 38292040
Background: Pre-exposure vaccination with MVA-BN has been widely used against mpox to contain the 2022 outbreak. Many countries have defined prioritized strategies, administering a single dose to those historically vaccinated...
8.
Pharmacokinetics of tecovirimat in subjects with Mpox
Tempestilli M, Mondi A, DAvolio A, Forini O, Pinnetti C, Mazzotta V, et al.
Int J Antimicrob Agents . 2023 Dec; 63(2):107068. PMID: 38141836
Objective: To investigate the pharmacokinetics (PK) of tecovirimat in subjects with Mpox. Methods: This monocentric, prospective, observational study enrolled subjects with Mpox who received standard treatment with oral tecovirimat. Plasma...
9.
Risk Awareness as a Key Determinant of Early Vaccine Uptake in the Mpox Vaccination Campaign in an Italian Region: A Cross-Sectional Analysis
Del Duca G, Tavelli A, Mastrorosa I, Aguglia C, Lanini S, Brita A, et al.
Vaccines (Basel) . 2023 Dec; 11(12). PMID: 38140166
Background: we aim to investigate attitudes toward vaccination by analyzing empirical factors associated with vaccine acceptance in the Lazio region mpox vaccination (MpoxVax) campaign in Italy. Methods: all subjects who...
10.
Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV
Vergori A, Cozzi-Lepri A, Matusali G, Cicalini S, Bordoni V, Meschi S, et al.
Vaccines (Basel) . 2023 Dec; 11(12). PMID: 38140145
(1) Background: Waning of neutralizing and cell-mediated immune response after the primary vaccine cycle (PVC) and the first booster dose (BD) is of concern, especially for PLWH with a CD4...